This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

A Time to Test Biotechs' Strength


And biotechnology companies have "massively outperformed" this year, whereas pharmaceutical firms have not, International Strategy & Investment analyst Mark Schoenebaum said in a research note. "Are we in a biotech bubble right now? The consensus view is yes, we are," Schoenebaum said, citing a recent informal survey of his clients. "But we're only in the second or third inning and have several quarters of good performance ahead of us."

The fundamentals of biotech look good. There's lots of growth and generally any licensing deal offers three to five years of future milestones. As long as productivity is up, there's no problem, Schoenebaum said.

After all, we're not talking tulips here. These firms generally have years of experience, both managerial and scientific, with solid hypotheses and some proof-of-concept data before they go public.

"There are window periods and often a period of high valuation coincides with a pretty robust stock market in general," Mendelson said.

"In life sciences M&A you usually have a couple of deep-pocketed suitors looking at a scarce asset. When that happens, yes, values can and do go up pretty high," said Dimitri Drone, of PricewaterhouseCoopers' life science practice.

Yet, in some circumstances, prices can rise too high, too fast. Onyx Pharmaceuticals Inc.'s (ONXX) stock price skyrocketed by nearly 50%, from $89 to $136, after it rejected Amgen Inc.'s (AMGN) $120 per share, $10 billion bid and then put itself up for sale. The higher price was enough to make Amgen and other deep-pocketed suitors rock back on their heels and ask for a closer look at what they might be buying. (A possible deal reportedly is still in the works.)

And just as negative macroevents can slow down action in a market, so can positive ones. Biotech has had several successes lately and those have raised the public's view of the industry. There are solid underlying reasons why the biotechnology industry is finally gaining interest from investors, Mendelson noted. The genomics revolution has had a major impact on how these firms analyze and develop their programs. Medicines are becoming more specific, and they're being developed based on genetic knowledge and manipulation. Those technologies have also made drug development more efficient.

3 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs